Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...

AAVantgarde Bio has announced the successful closing of a $141 million (€122 million) Series B financing round that was ...

Iron dysregulation contributes to oxidative stress, inflammation, and ferroptosis, driving retinal degeneration in dry AMD ...

Marguerite B. McDonald, MD, FACS, reflects on a first-year residency case that taught her the importance of trusting her ...

Deborah Ristvedt, DO, recalls a retinal detachment repair that took an unexpected turn, teaching lasting lessons in patient ...

The program begins with a discussion on the everyday challenges eye care professionals face in recognizing subtle signs of ...

James Chelnis, MD, FACS, is an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye. At the 2025 American ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

Specialists discuss diagnostic technologies, treatment strategies, and research that are improving outcomes for young ...

In celebration of Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had ...

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...